Nitric Oxide Synthase 2 Promoter Polymorphism Is a Risk Factor for Allergic Asthma in Children

Joanna Nowakowska1, Paulina Sobkowiak2, Anna Bręborowicz2

  • 1Molecular and Cell Biology Unit, Poznan University of Medical Sciences, 60-572 Poznan, Poland.

Insights

A specific variant in the NOS2 gene is linked to childhood asthma in Polish children. This finding may help identify new risk factors and personalize asthma treatments.

Area of Science:

  • Genetics and immunology
  • Pediatric respiratory medicine

Background:

  • Childhood atopic asthma correlates with eosinophil counts and airway inflammation, measured by exhaled nitric oxide (FeNO).
  • FeNO is a biomarker for atopic asthma, suggesting nitric oxide synthesis gene polymorphisms as potential risk factors.

Purpose of the Study:

  • To investigate the association between nitric oxide synthase (NOS) gene variants and childhood asthma.
  • To analyze specific single nucleotide polymorphisms (SNPs) in NOS1, NOS2, and NOS3 genes within the Polish population.

Main Methods:

  • Genotyping of 4 SNPs across 3 NOS genes in 443 children (220 with atopic asthma, 223 controls).
  • Utilized polymerase chain reaction with restriction fragments length polymorphism (PCR-RFLP) for genotyping.

Main Results:

  • A significant association was found for SNP rs10459953 in the NOS2 gene between asthma cases and controls (p=0.001 for genotypes, p=0.0006 for alleles).
  • No significant associations were observed for the other analyzed polymorphisms.

Conclusions:

  • A 5'UTR variant in the NOS2 gene may influence asthma susceptibility in Polish children.
  • Further functional studies are needed to elucidate the role of iNOS polymorphism in NOS2 translation and its potential as a novel childhood asthma risk factor.
  • This research could inform improved diagnosis and personalized asthma therapies.

Related Concept Videos

Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
3.3K
Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.8K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
812
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.3K
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
660
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
662